Achieve Life Sciences, Inc. (NASDAQ:ACHV) Shares Sold by Shay Capital LLC

Shay Capital LLC lowered its stake in Achieve Life Sciences, Inc. (NASDAQ:ACHV - Free Report) by 94.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 25,000 shares of the biopharmaceutical company's stock after selling 425,000 shares during the quarter. Shay Capital LLC owned about 0.07% of Achieve Life Sciences worth $88,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of ACHV. Barclays PLC lifted its position in Achieve Life Sciences by 303.1% in the third quarter. Barclays PLC now owns 47,655 shares of the biopharmaceutical company's stock valued at $226,000 after buying an additional 35,832 shares during the last quarter. SG Americas Securities LLC increased its stake in Achieve Life Sciences by 74.8% during the fourth quarter. SG Americas Securities LLC now owns 19,886 shares of the biopharmaceutical company's stock worth $70,000 after purchasing an additional 8,512 shares during the period. Sigma Planning Corp purchased a new stake in Achieve Life Sciences during the fourth quarter worth about $37,000. SBI Securities Co. Ltd. purchased a new stake in Achieve Life Sciences during the fourth quarter worth about $49,000. Finally, Raymond James Financial Inc. purchased a new stake in Achieve Life Sciences during the fourth quarter worth about $554,000. Institutional investors and hedge funds own 33.52% of the company's stock.

Achieve Life Sciences Trading Down 1.5%

NASDAQ:ACHV traded down $0.05 on Tuesday, reaching $3.26. 561,345 shares of the company's stock were exchanged, compared to its average volume of 192,868. The company has a quick ratio of 6.78, a current ratio of 6.78 and a debt-to-equity ratio of 0.31. The firm has a market capitalization of $113.07 million, a price-to-earnings ratio of -2.88 and a beta of 1.49. The business has a fifty day moving average of $2.49 and a 200-day moving average of $3.28. Achieve Life Sciences, Inc. has a 52-week low of $1.84 and a 52-week high of $5.59.

Achieve Life Sciences (NASDAQ:ACHV - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The biopharmaceutical company reported ($0.37) EPS for the quarter, hitting analysts' consensus estimates of ($0.37). As a group, analysts expect that Achieve Life Sciences, Inc. will post -1.17 earnings per share for the current year.

Insider Transactions at Achieve Life Sciences

In related news, CFO Mark K. Oki acquired 10,000 shares of the stock in a transaction dated Monday, March 17th. The stock was acquired at an average cost of $2.89 per share, with a total value of $28,900.00. Following the completion of the transaction, the chief financial officer now owns 10,000 shares in the company, valued at $28,900. This represents a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 2.00% of the company's stock.

Achieve Life Sciences Profile

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.